NeoGenomics, Inc. $NEO Shares Sold by Kopp Family Office LLC

Kopp Family Office LLC reduced its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 43.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 463,860 shares of the medical research company’s stock after selling 350,721 shares during the period. NeoGenomics accounts for about 2.3% of Kopp Family Office LLC’s holdings, making the stock its 15th biggest holding. Kopp Family Office LLC owned approximately 0.36% of NeoGenomics worth $3,581,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Headlands Technologies LLC purchased a new stake in shares of NeoGenomics in the 2nd quarter valued at approximately $32,000. AlphaQuest LLC acquired a new position in NeoGenomics in the first quarter valued at approximately $60,000. Capstone Financial Advisors Inc. purchased a new position in NeoGenomics in the second quarter worth approximately $73,000. Captrust Financial Advisors acquired a new stake in NeoGenomics during the second quarter worth $75,000. Finally, Gamco Investors INC. ET AL acquired a new stake in NeoGenomics during the second quarter worth $80,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

NeoGenomics Stock Down 0.2%

Shares of NEO opened at $12.28 on Friday. The stock has a market capitalization of $1.59 billion, a PE ratio of -13.95 and a beta of 1.60. NeoGenomics, Inc. has a 1 year low of $4.72 and a 1 year high of $19.11. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.62 and a current ratio of 3.91. The company’s 50-day simple moving average is $11.15 and its 200-day simple moving average is $8.69.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. The firm had revenue of $187.80 million during the quarter, compared to analysts’ expectations of $183.85 million. NeoGenomics had a negative net margin of 16.00% and a negative return on equity of 3.36%. The business’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.05 earnings per share. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. Analysts forecast that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

NEO has been the subject of a number of research analyst reports. Cowen reiterated a “buy” rating on shares of NeoGenomics in a report on Friday, September 12th. Needham & Company LLC upped their target price on shares of NeoGenomics from $8.00 to $14.00 and gave the company a “buy” rating in a research report on Friday, August 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeoGenomics in a research report on Monday. Leerink Partners set a $14.00 price objective on shares of NeoGenomics in a report on Tuesday, October 28th. Finally, TD Cowen increased their price objective on shares of NeoGenomics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Six research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $12.00.

Insider Buying and Selling at NeoGenomics

In other news, EVP Alicia C. Olivo sold 20,916 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $12.00, for a total value of $250,992.00. Following the sale, the executive vice president directly owned 31,083 shares in the company, valued at approximately $372,996. This trade represents a 40.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.40% of the company’s stock.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.